Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …